The VITALITY-HFpEF trial (Evaluate the Efficacy and Safety of the Oral sGC Stimulator Vericiguat to Improve Physical Functioning in Daily Living Activities of Patients With Heart Failure and Preserved Ejection Fraction) is designed to determine the efficacy and safety of a novel oral soluble guanylate cyclase stimulator, vericiguat, on quality of life and exercise tolerance in heart failure patients with preserved ejection fraction (HFpEF)


The VITALITY-HFpEF study was presented on June 12, 2020 during HFA Discoveries, an online initiative from the European Society of Cardiology Heart Failure Association.

Please note a My ESC account is required to view the on-demand webinar presentation for VITALITY-HFpEF


Paul W. Armstrong; Carolyn S. P. Lam, Kevin J. Anstrom, Justin Ezekowitz, Adrian F. Hernandez, Christopher M. O’Connor, Burkert Pieske, Piotr Ponikowski, Sanjiv J. Shah, Scott D. Solomon, Adriaan A. Voors, Lilin She, Vanja Vlajnic, Francine Carvalho, Luke Bamber, Robert O. Blaustein, Lothar Roessig, Javed Butler; for the VITALITY-HFpEF Study Group. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. JAMA. 2020;324:1512-1521. doi:10.1001/jama.2020.15922.

Javed Butler, Carolyn S P Lam, Kevin J Anstrom, Justin Ezekowitz, Adrian F Hernandez, Christopher M O’Connor, Burkert Pieske, Piotr Ponikowski, Sanjiv J Shah, Scott D Solomon, Adriaan A Voors, Yi Wu, Francine Carvalho, Luke Bamber, Robert O Blaustein, Lothar Roessig, Paul W Armstrong. Rationale and Design of the VITALITY-HFpEF Trial. Circ Heart Fail. 2019 May;12:e005998. doi: 10.1161/CIRCHEARTFAILRE.119.005998.

Media Coverage

New Vericiguat Shine May Not Brighten Heart Failure With Preserved LVEF (Medscape)
Audio Editor’s Summary of Vericiguat for HFpEF (JAMA)

Data Sharing

View the VITALITY-HFpEF Data Sharing Appendix here.